Careers Contact Us

EN

CN

R&D and Innovation

R&D and Innovation

Driven by independent innovation, continuously building a differentiated R&D pipeline for metabolic and chronic diseases

Programs
Indications
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Launched

Bofanglutide Injection

GZR18

>

Weight management in people with obesity or overweight

CN
US

Moderate to severe obstructive sleep apnea

CN

Type 2 diabetes mellitus

CN
US

Insulin Ludefen

GZR4

>

Type 2 diabetes mellitus

CN
EU

GZR101 Injection

>

Type 1/ Type 2 diabetes mellitus

CN

GZR33 Injection

>

Type 2 diabetes mellitus

CN
EU

GZR102 Injection

>

Type 2 diabetes mellitus

CN

GZC8072 Tablets

>

Weight management in people with obesity or overweight

CN

Type 2 diabetes mellitus

CN

GLR1075 Injection

>

Cirrhotic Ascites with Hypoalbuminemia

CN

GLR2037 Tablets

AR(PROTAC)

>

Advanced prostate cancer

CN

GLR2038 Tablets

ER(PROTAC)

>

Advanced breast cancer

CN

Bempedoic Acid

>

Hyperlipidaemia

CN

Mesalazine Enteric-coated Sustained-release Capsules

>

Ulcerative colitis

CN

Insulin Glargine

>

Diabetes mellitus

CN
EU
US

Insulin Aspart

>

Diabetes mellitus

CN
EU
US

Insulin Aspart 30

>

Diabetes mellitus

CN

Insulin Lispro

>

Diabetes mellitus

CN
EU
US

Insulin Lispro 25

>

Diabetes mellitus

CN

Recombinant Human Insulin 30

>

Diabetes mellitus

CN

Sitagliptin Phosphate Tablets

>

Type 2 diabetes mellitus

CN

Linagliptin Tablets

>

Type 2 diabetes mellitus

CN

Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II)

>

Type 2 diabetes mellitus

CN

Empagliflozin Tablets

>

Type 2 diabetes mellitus, cardiac failure

CN